Effekten som monoterapi er blevet evalueret i et randomiseret, dobbeltblindet, placebokontrolleret studie over 2 år (AFFIRM studiet) med relapsing- remitting MS- patienter, der havde oplevet mindst ét klinisk attak i året forud for deres indtræden i forsøget, og som havde en score på mellem 0 og 5 på Kurtzke- skalaen (Expanded Disability Status Scale - EDSS).
Efficacy as monotherapy has been evaluated in one randomised, double-blind, placebo-controlled study lasting 2 years (AFFIRM study) in relapsing-remitting MS patients who had experienced at least 1 clinical relapse during the year prior to entry and had a Kurtzke Expanded Disability Status Scale (EDSS) score between 0 and 5.